These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35481309)

  • 41. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
    West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
    Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection.
    Atemnkeng F; Alataby H; Demirjian J; Kenne FM; Nfonoyim J
    J Med Cases; 2021 Mar; 12(3):94-98. PubMed ID: 33984091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
    Singh AK; Oks M; Husk G; Dechario SP; Mina B; Singh K; Kirschenbaum L; Carpati CM; Mahmoud O; Gabra NI; Ishikawa O; Altschultz E; Shah V; Mahajan A; Gautam A; Birnbaum B; Antonacci AC; Raoof S
    Respir Care; 2021 Dec; 66(12):1805-1814. PubMed ID: 34548407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
    Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
    Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of Tocilizumab in the Treatment of a Recent Kidney Transplant Recipient With COVID-19.
    Chikobava E; Chkhikvadze L; Menabde K; Pkhakadze G; Tchokhonelidze I
    Cureus; 2024 Jan; 16(1):e53163. PubMed ID: 38420098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The therapeutic effect of high flow nasal cannula oxygen therapy for the first imported case of Middle East respiratory syndrome to China].
    Luo Y; Ou R; Ling Y; Qin T
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Oct; 27(10):841-4. PubMed ID: 27132449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Case of Abdominal Perforation in a COVID+ Patient Treated With Tocilizumab and Corticosteroids.
    Chaudhry B; Alekseyev K; Didenko L; Chaudhry M
    Clin Med Insights Case Rep; 2023; 16():11795476231173870. PubMed ID: 37342097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission.
    Sánchez-Rovira P; Pérez-Chica G; Ortega-Granados AL; Aguilar-García J; Díaz-Beltrán L; Gálvez-Montosa F; García-Verdejo F; Luque-Caro N; Quero-Blanco C; Fernández-Navarro M; Rodríguez-Sánchez A; Ruiz-Bailén M; Yaguez-Mateos L; Marín-Pozo JF; Sierra-Torres MI; Lacárcel-Bautista C; Duro-Ruiz GJ; Duro-Fernández MÁ; García-Alegría J; Herrero-Rodríguez C
    Medicine (Baltimore); 2021 Jul; 100(29):e26533. PubMed ID: 34398008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis.
    Zhang J; Fan X; Zhang X; Jiang F; Wu Y; Yang B; Li X; Liu D
    Front Pharmacol; 2023; 14():1293331. PubMed ID: 38074144
    [No Abstract]   [Full Text] [Related]  

  • 51. Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study.
    Roddy J; Wells D; Schenck K; Santosh S; Santosh S
    Crit Care Explor; 2022 May; 4(5):e0702. PubMed ID: 35783551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe COVID-19 during pregnancy treated with pulse corticosteroid therapy and mid-trimester termination: A case report.
    Bui TN; Huynh NM; Do-Tran NH; Ngo HA; Tran H; Nguyen NT; Pham TT; Le KD; Nguyen TA
    Case Rep Womens Health; 2022 Apr; 34():e00396. PubMed ID: 35165651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
    Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
    J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Efficacy of Combination Therapy of Remdesivir, Baricitinib, and High-dose Steroids in Patients Hospitalized with Moderate to Severe COVID-19.
    Nagasawa R; Niwa T; Hagiwara E; Oda T; Yamada S; Okuda R; Baba T; Komatsu S; Kaneko T; Ogura T
    Intern Med; 2023 Nov; 62(21):3125-3130. PubMed ID: 37438142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports.
    Abdullah S; Bashir N; Mahmood N
    J Med Case Rep; 2021 Aug; 15(1):426. PubMed ID: 34364393
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms.
    Muschitz C; Trummert A; Berent T; Laimer N; Knoblich L; Bodlaj G; Krainer A; Linder C; Resch H
    Wien Klin Wochenschr; 2021 Sep; 133(17-18):973-978. PubMed ID: 33905029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients.
    Zeng J; Xie MH; Yang J; Chao SW; Xu EL
    World J Clin Cases; 2020 Sep; 8(17):3763-3773. PubMed ID: 32953852
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.
    Melody M; Nelson J; Hastings J; Propst J; Smerina M; Mendez J; Guru P
    Immunotherapy; 2020 Oct; 12(15):1121-1126. PubMed ID: 32546029
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia.
    Nair PR; Haritha D; Behera S; Kayina CA; Maitra S; Anand RK; Ray BR; Soneja M; Subramaniam R; Baidya DK
    Respir Care; 2021 Dec; 66(12):1824-1830. PubMed ID: 34584010
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19).
    Ullah S; Abid R; Haider S; Khuda F; Albadrani GM; Abdulhakim JA; Altyar AE; Abdel-Daim MM; Halimi SMA; Khalil AAK
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.